ArticleJournal of molecular histology2026
Study of the potential protective efficacy of lactoferrin on indomethacin-induced gastric fundic mucosal injury in rats.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric mucosal injury is one of the most prevalent gastrointestinal disorders. Lactoferrin, a multifunctional glycoprotein, is recognized for its potent antioxidant and anti-inflammatory properties. This study investigated the protective and therapeutic potential of lactoferrin against indomethacin-induced gastric fundic mucosal injury. Forty-two male rats were randomized into four groups: the control group (Group I), which was further subdivided into subgroup IA (which received normal saline) and subgroup IB (which received a daily oral dose of 300 mg/kg Lf); the indomethacin-only group (Group II), which received a single oral dose of indomethacin (60 mg/kg) and was then subdivided into subgroup IIA (euthanized 6 h post-induction) and subgroup IIB (euthanized 21 days post-induction); the lactoferrin-pretreated group (Group III), which received 300 mg/kg/day Lf for 21 days, received a single oral dose of indomethacin (60 mg/kg) on the 22nd day, and was then subdivided into subgroup IIIA (euthanized 6 h post-induction) and subgroup IIIB (euthanized 21 days post-induction); and the lactoferrin-treated group (Group IV), which received a single oral dose of indomethacin (60 mg/kg) and then received a daily oral dose of Lf at 300 mg/kg for 21 days. Gastric tissues were processed for histomorphometric and biochemical assessments. In the indomethacin-only group, subgroup IIA showed extensive hemorrhagic lesions and mucosal erosions, while subgroup IIB exhibited deeper ulcerations. The lactoferrin-pretreated group (Group III) showed a significant reduction in the extent and severity of mucosal erosions at both time points, with the 21-day recovery (subgroup IIIB) showing superior outcomes. Notably, prophylactic lactoferrin administration in Group III demonstrated higher efficacy in preserving mucosal integrity compared to the post-injury therapeutic regimen of Group IV. In conclusion, our findings suggest that Lactoferrin may exert a gastroprotective effect associated with the modulation of antioxidant, anti-inflammatory, and anti-apoptotic pathways. Moreover, prophylactic administration of lactoferrin demonstrated potential in mitigating acute mucosal damage and supporting tissue repair within this model.
Indexed as
Identifiers
42461525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.